VNDA On Watch, NUVA Q2 Results Miss Estimates, MRTX Awaits FDA Decision...

NuVasive Inc. (NUVA), a company focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, has reported lower-than-expected earnings and sales for the second quarter of 2022.

from RTT - Top Story https://ift.tt/bV9LkGH
via IFTTT